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The tumor microenvironment comprises newly formed blood and lymphatic vessels which shape the influx, retention and departure of
lymphocytes within the tumor mass. Thus, by influencing the intratumoral composition of lymphocytes, these vessels affect the man-
ner in which the adaptive immune system responds to the tumor, either promoting or impairing effective antitumor immunity. In our
study, we utilized a mouse model of carcinogen-induced fibrosarcoma to examine the composition of tumor-infiltrating lymphocytes
during tumor progression. In particular, we sought to determine whether CD41Foxp31 regulatory T cells (Tregs) became enriched dur-
ing tumor progression thereby contributing to tumor-driven immunosuppression. This was not the case as the proportion of Tregs and
effector CD41 T cells actually declined within the tumor owing to the unexpected accumulation of na€ıve T cells. However, we found no
evidence for antigen-driven migration of these T cells or for their participation in an antitumor immune response. Our data support the
notion that lymphocytes can enter tumors via aberrantly formed blood and lymphatic vessels. Such findings suggest that targeting
both the tumor vasculature and lymphatics will alter the balance of lymphocyte subpopulations that enter the tumor mass. A consider-
ation of this aspect of tumor immunology may be critical to the success of solid cancer immunotherapies.
A body of evidence indicates that activation of tumor-speciﬁc
T cells is an essential prerequisite for immune-mediated
tumor control (reviewed in Ref. 1). Such evidence for a role of
effector T cells in cancer immunity is provided by direct
studies in mice, and indirect studies of patients with cancer
(reviewed in Ref. 1). However, the immunosuppressive nature
of the tumor microenvironment is believed to limit the effec-
tor functions of tumor-speciﬁc T cells (reviewed in Ref. 2),
preventing them from killing tumor cells and halting tumor
progression. Multiple mechanisms may contribute to this
immunosuppressive environment, including notably, the sup-
pressive effects of Foxp31 regulatory T cells (Tregs). Indeed,
an increased frequency of Tregs is often associated with
tumor progression.3
The type of lymphocyte that enters and accumulates
within the tumor mass will be inﬂuenced by a variety of fac-
tors. These include the type of blood and lymphatic vessels
developing around and within the tumor, the chemokines
and adhesion molecules expressed by these vessels and within
the tumor parenchyma and also on the antigen speciﬁcity of
the inﬁltrating T cells. As the combination of receptors for
chemokines and adhesion molecules varies between different
T-cell subsets, cues enabling migration and retention of lym-
phocytes will favor particular T-cell subsets (reviewed in Ref.
4) and hence dictate the composition of the tumor-
inﬁltrating T-cell pool. In our study, we sought to examine
the composition of the tumor-inﬁltrating CD41 T cell pool
in mouse tumors developing in vivo and how this alters with
tumor progression. For this purpose, we used the chemical
carcinogen methylcholanthrene (MCA) to induce de novo
ﬁbrosarcomas in mice and examined the composition of the
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tumor-inﬁltrating T-cell pool during tumor progression. The
results our study were, however, unexpected as although we
observed a pronounced shift in CD41 T-cell subsets with
tumor progression, this was not owing to an increase in con-
ventional effector T cells or Tregs but rather owing to the
accumulation of na€ıve T cells which eventually dominated
the pool of tumor-inﬁltrating CD41 T-lymphocytes. We then
proceeded to examine the mechanisms underpinning the shift
toward na€ıve T-cell accumulation within tumors focussing on
the role of the tumor vasculature and lymphatics.
Material and Methods
Mice
Six- to eight-week-old female C57BL/6 (Thy1.1) and Foxp3-GFP
(Thy1.2) transgenic mice were used. These mice were housed in
speciﬁc pathogen-free conditions and all experiments were con-
ducted in compliance with UK Home Ofﬁce regulations.
Tumor induction
Mice were anaesthetized and injected subcutaneously (in the
hind leg) with 400 mg of 3-MCA (Sigma Aldrich, Dorset,
UK) in 100 mL of olive oil. Tumors occurred between 80 and
150 days after injection. Their development was monitored
periodically and mice bearing tumors were culled before the
tumors reached 1.5 cm in diameter. Mice showing discomfort
or difﬁculty in walking were culled irrespective of the tumor
size.
Lymphocyte isolation
Spleens, tumor-draining inguinal lymph nodes and the con-
tralateral nondraining lymph nodes were disrupted by mash-
ing through a 40-mm nylon cell strainer (BD Falcon, Oxford,
UK) using a sterile 2-mL syringe plunger. Tumors were
excised and chopped into pieces using scalpel blades. The
pieces were then mashed with a syringe plunger and the
resulting cell suspension was passed through several 70-mm
nylon cell strainers (BD Falcon). The cell suspensions were
centrifuged, and red blood cells were lysed using ammo-
nium–chloride–potassium lysis buffer (Gibco, Paisley, UK).
Flow cytometry and antibodies
Mononuclear cells isolated from spleens, lymph nodes and
tumors were ﬁrst stained with a dead cell marker (LIVE/
DEAD Fixable Aqua stain; Invitrogen, Paisley, UK) according
to the manufacturer’s instructions. Cells were washed and
then stained for cell-surface markers and chemokine recep-
tors. Stained cells were washed, ﬁxed and acquired on a ﬂow
cytometer (FACS Canto II, BD). Data analysis was performed
using Summit 4.3 software. The following antibodies were
used: CD4-Paciﬁc Blue (Biolegend, San Diego, USA), CD44-
PerCP Cy5.5 (ebioscience, San Diego U) or CD44-FITC (BD-
Pharrmingen, San Diego, USA), CD62L-PE-Cy7 (eBio-
science), CCR7-APC (eBioscience), FoxP3 expression was
detected by GFP ﬂuorescence.
Histology
MCA tumors were collected from mice and ﬁxed in neutral
buffered formalin and embedded in parafﬁn. Sections of 5
mm in thickness, were cut and mounted on slides, dewaxed
in xylene and hydrated using graded alcohols to tap water.
Sections were stained for 3 min in Harris Haematoxylin solu-
tion (Thermos scientiﬁc, Waltham, USA), washed in tap
water for 5 min before blueing in Scotts Tap Water for 1
min. Sections were then washed in tap water and stained in
Eosin solution (Sigma-Aldrich) for 2 min before dehydrating
in an ethanol series and mounting in DPX (BDH).
Evans Blue
In all, 80 mL of Evans Blue Dye (1% w/v, Sigma-Aldrich) was
injected into the base of the leg and approximately 60 min
later tumor, inguinal and popliteal lymph nodes were
removed and then photographed and either prepared for
immunohistochemistry or dye was extracted using formamide
and measured by spectrophotometry.
Fluorescein isothiocyanate–dextran
In brief, 50–100 mL of ﬂuorescein isothiocyanate (FITC)–dex-
tran (5,000 kDa; 10 mg/mL; Sigma-Aldrich) was injected into
the base of the leg and approximately 60 min later tumor,
inguinal and popliteal lymph nodes were removed and pre-
pared for immunohistochemistry.
Immunohistochemistry
Frozen sections. MCA tumors and lymph nodes from mice
injected with Evans Blue Dye or FITC Dextran were embed-
ded in optimum cutting temperature (OCT) compound (RA
Lamb) and snap frozen. Sections, 5 mm in thickness, were
ﬁxed for 10 min in ice-cold acetone and left to dry at room
temperature. Slides were washed in phosphate-buffered saline
(PBS) and blocked with 2.5% of normal horse serum (Vector
Labs, Petersborough, UK) in PBS for 30 min. Sections were
What’s new?
It is well known that a tumors’ microenvironment can impair the anti-tumor immune response. The culprits are usually
assumed to be various suppressor cells and cytokines. In this study, however, the authors found that seemingly innocuous,
na€ıve T cells may also play a significant role—simply by accumulating and possibly out-competing activated effector cells
within the tumor. A better understanding of the signals produced by the tumor microenvironment may allow researchers to
alter this T-cell pool, thus enhancing the immune response.
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stained overnight at 4C with rabbit polyclonal anti-LYVE-15
(Dr. David Jackson; Oxford University, Oxford, United King-
dom), rat anti-CD31-FITC (clone 390; eBioscience) and bio-
tinylated rat anti-mouse CD169 (clone MOMA-1; Abcam,
Cambridge, UK). Primary antibodies were detected with
Alexa Fluor 568 donkey anti-rabbit, Alexa Fluor 488 goat
anti-rat, Alexa Fluor streptavidin 555, Alexa Fluor 488 goat
anti-rabbit (Invitrogen Life Sciences). Sections were some-
times counter stained with TOTO-3 (Invitrogen Life Scien-
ces) to detect nuclei. Sections were mounted in Vectashield,
containing 4,6-diamidino-2-phenylindole (DAPI) (Vector
Labs). Images were collected with a Zeiss LSM5 Pascal confo-
cal microscope. Images were assembled in Adobe Photoshop
software.
Parafﬁn sections. MCA tumors were collected from mice
and ﬁxed, embedded, cut and dewaxed as mentioned above.
After performing antigen retrieval, by microwaving in 10 mM
of Tris, 1 mM of ethylenediaminetetraacetic acid buffer, pH 9,
for 8 min, sections were cooled for 30 min and then equili-
brated in PBS. Nonspeciﬁc antibody binding was blocked by
incubating sections with 2.5% of normal horse serum (Vector
Labs) in PBS for 30 min. Sections were stained overnight at 4C
with goat polyclonal anti-CCL21 antibody (R1D Systems,
Abingdon, UK) rabbit polyclonal anti-LYVE-15 (Dr. David
Jackson Oxford University, Oxford, United Kingdom), and rat
anti-CD31 (clone SZ31; Dianova, Hamburg, Germany). Pri-
mary antibodies were detected with Alexa Fluor 555 donkey
anti-goat, Alexa Fluor 488 donkey anti-rabbit, Alexa Fluor 568
goat anti-rat and Alexa Fluor 488 donkey anti-rat (Invitrogen
Life Sciences). Sections were counter stained with TOTO-3
(Invitrogen Life Sciences) to detect nuclei. Sections were
mounted in Vectashield, containing DAPI (Vector Labs).
Images were collected with a Zeiss LSM5 Pascal confocal micro-
scope. Images were assembled in Adobe Photoshop software.
T-cell transfer
Spleen cells puriﬁed from na€ıve wild-type (WT) or CCR72/2
animals were loaded with the ﬂuorescent dye label PKH26
(Sigma-Aldrich) or CFSE, respectively, and 3 3 107 cells
were injected (100 mL) into the base of the hind leg. Single-
cell suspensions were prepared from the inguinal lymph
nodes and tumors 24 hr later, stained with antibodies against
CD4. Stained cells were analyzed by ﬂow cytometry as
described above.
T-cell receptor repertoire analyses
For cell sorting, cells were stained with anti-CD4 Paciﬁc Blue
(BD), anti-CD25 PE (eBioscience), anti-CD44 APC (BD) and
anti-CD62L PE-Cy7 (eBioscience). Cell sorting was per-
formed using a customized 20-parameter FACSAria II ﬂow
cytometer (BD). CD41GFP1 lymphocytes were sorted as
Tregs and CD41GFP2 lymphocytes were sorted as conven-
tional T cells (Tconv). Tconv were further separated into
antigen-experienced (CD44hiCD62Llo) and na€ıve T cells.
Post-sort purity was >98% in all cases. RNA was extracted
from sorted cells using a magnetic column-based RNA
extraction kit (Miltenyi, Surrey, UK). cDNA was reverse tran-
scribed from 30 to 200 ng of total RNA using Superscript III
(Invitrogen) with random hexamers. For the analysis of the
total T-cell receptor (TCR) repertoire, an unbiased template-
switch anchored RT-PCR was used as described previously.6
The PCR products were then transformed into chemically
competent Escherichia coli (TOP10; Invitrogen) and grown
on selective LB plates (100 mg/mL ampicillin with IPTG and
X-gal for blue/white screening). Up to 96 colonies per sort
were picked and DNA sequenced (Beckman Coulter,
Danvers, USA). The TRB gene usage and CDR3 amino acid
composition was established using IMGT/V-QUEST software.
RNA extraction and gene expression analysis
Tumor and LN samples were cut in 10-mM sections from
frozen OCT-embedded tissue and RNA was extracted using
TRIzol reagent (Invitrogen). Quantity and quality of RNA
were determined by the Agilent 2100 bioanalyzer (Agilent
Technologies, Wokingham, UK), and only high-quality sam-
ples with an RIN (RNA intergrity number) of 8 were used
for gene expression analysis. Gene expression proﬁling was
carried out using MouseRef-8v2.0 whole genome expression
bead chip (Illumina) as recommended by the manufacturer.
Probe intensity values were corrected by background subtrac-
tion in GenomeStudio software and subsequently log-2 and
baseline (median) transformed using Genespring software
(Agilent Technologies) before the analsyis of genes.
Results
Composition of the tumor-infiltrating CD41 T-cell pool
Fibrosarcomas were induced in mice approximately 80–150
days after injection of the carcinogen, MCA. The relative
proportions of CD41 Foxp32 and CD41 Foxp31 T cells
among tumor-inﬁltrating lymphocytes (TILs) were assessed
and (Fig. 1a) there was a large range in Treg representation
within the tumor-inﬁltrating T-cell pool (7–42%). The ratio
of Foxp32 cells and Foxp31 cells among CD41 lymphocytes
from disaggregated tumors (average, 4:1) was different from
that observed in blood (average, 19:1, data not shown and
Ref. 7), implying that these lymphocytes are tumor-
inﬁltrating cells and not simply blood-borne contaminants.
To further delineate the phenotype of these CD41 T-cell
populations, a detailed phenotypic analysis of CD41 TILs
was performed. Distinct subpopulations of CD41 T cells
within the tumor were observed as deﬁned by the expression
of CD62L and CCR7. Although the majority of CD41Foxp31
T cells (Tregs) were CD62LloCCR72 and hence of an effector
memory (Tem) phenotype (Figs. 1b and 1d), we found that
on average less than half of the CD41Foxp32 T cells were
Tem cells (Figs. 1c and 1e). Notably, within the CD41Foxp32
population, a signiﬁcant number of cells expressed both
CD62L and CCR7, markers compatible with a na€ıve or cen-
tral memory T-cell phenotype.8 Costaining with CD44
revealed low CD44 expression on the majority of the
T
u
m
or
Im
m
un
ol
og
y
2158 Naive T cells in carcinogen-induced tumors
Int. J. Cancer: 134, 2156–2167 (2014) VC 2013 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
CD62Lhi TILs, supporting the premise that these cells are of
a na€ıve phenotype (Fig. 1f and Supporting Information Fig.
1). This phenomenon contrasted with CD41 T cells recov-
ered from the lungs of inﬂuenza-infected mice, where almost
all were CD44hi, that is they have an activated phenotype. As
expected, the majority of CD62LhiCD41 T cells in the thy-
mus have low CD44 expression indicative of a na€ıve pheno-
type (Supporting Information Fig. 1).
Tumor-infiltrating CD44loCD62LhiCCR71 lymphocytes are
bona fide na€ıve CD41 T cells
As CD44loCD62LhiCCR71 T cells represented a signiﬁcant
population within the tumor-inﬁltrating CD41Foxp32 pool,
we sought to determine whether they were indeed na€ıve T
cells. These cells expressed high levels of CD27 (Fig. 2a),
compatible with a na€ıve phenotype.9 Short-term functional
assays were conducted whereby interferon (IFN)-g was meas-
ured after a brief period of stimulation with PMA/ionomycin.
Although IFN-g expression was observed among the CD44hi
cells, the CD44lo cells did not express IFN-g (Fig. 2b), con-
ﬁrming that these CD44lo cells are also functionally na€ıve. As
it has been reported that exhausted T cells, which express
PD-1 and Tim-3, can downregulate CD44, expression of
these markers was evaluated.10 Many TILs did indeed express
both markers but expression was conﬁned to CD44hi cells,
indicating that the CD44lo cells were not exhausted cells
Figure 1. A significant proportion of tumor-infiltrating CD41 T Cells are CD62LhiCCR71CD44lo. Tumor-cell suspensions were stained with
CD4-, Foxp3-, CD62L- and CCR7-specific monoclonal antibodies (mAbs) and analyzed by flow cytometry. Proportion of CD41 cells that are
Foxp32 or Foxp31 are shown (a). Examples of CD62L and CCR7 staining on gated CD41Foxp31 and CD41Foxp32 cells (b and c). Propor-
tions of tumor-infitrating CD41Foxp31and Foxp32 cells from spleens, tumors, draining and nondraining lymph nodes, represented as
CD62LhiCCR71, CD62LloCCR71 and CD62LloCCR72 (d and e) (n57). Expression of CD44 by CD62Lhi and CD62Llo cells (f).
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masquerading as na€ıve cells (Figs. 2c and 2d). Thus, in con-
clusion, these data demonstrate that a signiﬁcant number of
na€ıve T cells had indeed migrated to the tumor mass.
Route of entry of na€ıve CD41 T cells
Under nonpathological conditions, na€ıve lymphocytes mainly
recirculate between lymph nodes; however, there is evidence
that na€ıve T cells do enter nonlymphoid organs as part of
their normal migratory pathway (Ref. 11 and reviewed in
Ref. 12). As na€ıve T cells are signiﬁcantly enriched in the
tumors described above compared to the previous reports of
other tissues,11 it is likely that mechanisms other than those
that allow migration of na€ıve T cells into nonlymphoid
organs, under homeostatic conditions, are at play. It has been
reported that na€ıve T cells can access sites of chronic inﬂam-
mation and autoimmunity through neogenesis of high endo-
thelial venules (HEVs) within ectopic lymphoid structures.
HEVs are specialized blood vessels, which, under nonpatho-
logical conditions, are found only in secondary lymphoid
organs where they allow na€ıve T-cell entry (reviewed in Ref.
13). As we have reported previously, however, HEVs are not
found in unmanipulated MCA-induced ﬁbrosarcomas and
thus cannot account for the enrichment of na€ıve T cells in
these tumors.14
Tumor angiogenesis is a process through which new blood
vessels are formed to supply oxygen and nutrients required
to sustain tumor growth. This is a characteristically chaotic
process in tumors, leading to the development of irregular
and often leaky blood vessels (reviewed in Ref. 15). With this
fact in mind, it is possible that T cells, including na€ıve T
cells, could enter the tumor parenchyma randomly by egress
through these blood vessels. Upon examination of H&E-
stained ﬁbrosarcoma sections, red blood cells were clearly
observed outside blood vessels and moreover, areas of signiﬁ-
cant haemorrhage were readily detected within the tumor
mass (Fig. 3). These data clearly indicate that aberrantly
formed hyperpermeable blood vessels could serve as entry
points through which cells, including na€ıve T cells, could
enter the tumor mass. Leaky blood vessels may not com-
pletely account for the presence of na€ıve T cells within the
Figure 2. Tumor-infiltrating CD41CD62LhiCCR71CD44lo T cells are bona fide na€ıve T cells. Expression of CD27 and CD44 by CD41 T cells
derived from the tumor. Individual populations were gated (a) and analyzed for the expression of CD62L. Relative expression levels of
CD62L are indicated on the plot (a). Tumor cell suspensions were stained with CD4- and CD44-specific mAbs and subsequently stimulated
for 4 hr with PMA/ionomycin before intracellular staining for IFN-g. IFN-g staining was examined on lymphocytes gated as CD41CD44lo
(filled) and CD41CD44hi (black line) (b). Tumor cell suspensions were also stained with PD-1- and Tim3-specific mAbs and representative
plots are shown of either PD-1 and CD44 or Tim3 and CD44 on CD4-gated cells cells (c and d).
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tumors as the relative proportions of different T-cell subsets
in blood and tumors were, as mentioned above, distinct.
Tumor development is also associated with lymphatic
hyperplasia and the sprouting of new lymphatic vessels, proc-
esses that facilitate dissemination of cells from the primary
tumor via peritumoral lymphatics, and metastasis to tumor
draining lymph nodes (reviewed in Ref. 16). Here, we consid-
ered the novel possibility that the development of an
expanded network of lymphatics in and around ﬁbrosarco-
mas might facilitate entry of na€ıve T cells from neighboring
tissues via afferent lymph. In support of this hypothesis,
na€ıve T cells have been reported in afferent lymph, albeit in
lower numbers than memory cells.17 Uptake of lymph into
ﬁbrosarcomas was assessed by monitoring the accumulation
of Evans Blue Dye,18 after injection of the dye into the base
of the leg of a tumor-bearing mouse (Supporting Information
Fig. 2). After approximately 1 hr, the primary tumor, as well
as the draining ipsilateral and contralateral inguinal lymph
nodes, was removed for examination (Supporting Informa-
tion Fig. 2). Upon macroscopic inspection, tumors, as well as
the draining lymph nodes, were visibly blue (Supporting
Information Fig. 2). To conﬁrm dye uptake by the tumor,
Evans Blue Dye was extracted and measured by spectrometry
(Supporting Information Fig. 2). Finally, as Evans Blue Dye
is autoﬂuorescent, sections were prepared from tumors and
inguinal lymph nodes for examination by confocal micros-
copy. Uptake of dye in both tumors and draining lymph
nodes was clearly observed (Figs. 4a and 4b). To further
examine the tumors for the presence of a lymphatic network,
tumors from Evans Blue-injected mice were costained with
LYVE-1-, CD31- and MOMA-1-speciﬁc antibodies. Colocali-
zation of LYVE-1 with both CD31 and MOMA-1 was
observed, indicating the development of lymphatic vessels
and a subcapsular-sinus-like structure within the tumor. To
further conﬁrm that the lymphatic vessels can deliver lymph
constituents to the tumor, we injected dextran–FITC into
the base of the leg of a tumor-bearing mouse and stained
recovered tumors with LYVE-1-speciﬁc antibodies. As shown
in Figure 4c, we observed colocalization of dextran–FITC and
LYVE-1 within both draining lymph nodes and tumors.
Moreover, dextran–FITC could also be observed intratumor-
ally, indicating that lymph constituents can enter the tumor
body (Fig. 4c).
MCA-induced fibrosarcomas express the lymphoid
chemokine, CCL21
The majority of na€ıve T cells lack receptors for inﬂammatory
chemokine-mediated migration, the expression of which is
linked to T-cell activation. Na€ıve T cells express CCR7, a
chemokine receptor that binds to the homeostatic lymphoid
chemokines CCL19 and CCL21, which help direct and retain
na€ıve T cells in secondary lymph nodes. CCL21 is expressed
on lymphatic vessels where its synthesis is signiﬁcantly
increased in response to inﬂammation.19 It is reportedly
expressed by many tumors and there is evidence that exoge-
nous expression of CCL21 promotes accumulation of CCR71
cells and the development of stromal zones within tumors
resembling lymph node stroma.20 As conventional CD41 T
cells, but not Tregs, downregulate CCR7 upon activation, it
has been proposed that CCL21 expression in tumors serves
to preferentially attract Tregs thereby contributing to immu-
nosuppression within the tumor microenvironment.20 As
na€ıve CD41 T cells express CCR7 and many of these as well
as CCR71 Tregs are observed in the ﬁbrosarcomas described
here (Supporting Information Fig. 3), it was clearly of rele-
vance to determine whether these tumors express CCL21.
Figure 3. Blood vessels are leaky in MCA-induced tumors. Sections prepared from paraffin-embedded tumors were H&E stained and exam-
ined for red blood cells. Arrows point to red blood cells identified outside of blood vessels and H indicates areas of extensive haemor-
rhage. Scale bars: 100 mm.
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Gene expression analysis was performed using mRNA iso-
lated from individual tumors. As shown in Supporting Infor-
mation Figure 3, CCL21-ser (predominantly found in
lymphoid organs) and CCL21-leu (predominantly found in
lymphatics) were detected in tumors albeit at lower levels
than in lymph nodes. In contrast, we observed no expression
of the lymphoid chemokine, CCL19. To conﬁrm CCL21
expression in tumors, parafﬁn-embedded tumor sections
were prepared and stained with CCL21-speciﬁc antibodies
recognizing both CCL21 isoforms. CCL21 was observed in
Figure 4. Afferent lymphatic vessel function detected in MCA-induced tumors. Evans Blue was injected into the base of the leg and approxi-
mately 60 min later the tumor and draining lymph nodes were removed. Frozen sections were prepared and examined for Evans Blue auto-
fluorescence and also stained for LYVE-1 and CD31 (a) and MOMA-1 and LYVE-1 (b). FITC–dextran (5,000 kDa) was injected into the base
of the leg and approximately 60 min later the tumor and draining lymph nodes were removed. Frozen sections were prepared and stained
for LYVE-1 and were also counter stained with TOTO-3 to detect DNA. Low-power images are shown on the left and high-power images of
the area in the white box are shown on the right (c). Scale bars a, b, and c left: 100 mm. Scale bars c right: 20 mm.
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the ﬁbrosarcomas and costaining of sections with LYVE-1-
or CD31-speciﬁc antibodies, indicating colocalization of
CCL21 with lymphatic endothelial cells (Figs 5a–5c). .
To determine whether the CCL21–CCR7 axis is important
for mediating entry of lymphocytes via the lymphatics, we
loaded donor CCR72/2 and WT spleen cells with CFSE and
Figure 5. Afferent lymphatic vessels are CD311 and contain CCL21 in MCA-induced tumors. Frozen tumor sections were prepared and
stained for LYVE-1 and CCL21 (a), CD31 and LYVE-1 (b) and CCL21 and CD31 (c). All sections were also counter stained with TOTO-3 to
detect DNA. PKH26-labeled WT and CFSE-labeled CCR72/2 spleen cells were subcutaneously injected into the base of the leg of a tumor-
bearing mouse. Around 18 hr later, the tumors, draining and nondraining lymph nodes were harvested and single-cell suspensions were
stained with CD4-specific antibodies. Lymphocytes were gated using a live/dead marker and proportions of dye-labeled CD41 cells in each
of the three compartments are shown (d). Scale bars a–c: 20 mm.
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PKH26, respectively, prior to subcutaneous injection into
recipient tumor-bearing mice. After 18 hr, T cells were recov-
ered from the tumor and draining (inguinal) and nondraining
(contralateral inguinal) lymph nodes (Fig. 5d). At this time
point, we found virtually no transferred cells in the spleens and
contralateral lymph nodes of the recipient mice consistent with
migration via the lymph. In accordance with the previous
reports, we could recover WT but not CCR72/2 cells from the
draining inguinal lymph nodes supporting the previous stud-
ies, indicating that CCR7 regulates T-cell exit from peripheral
tissues.21 To our surprise, however, both WT and CCR72/2 T
cells could be recovered from tumors. These results suggest
that T cells can access ﬁbrosarcomas via lymphatics by a mech-
anism that does not involve the CCL21/CCR7 axis.
Figure 6. The proportion of intratumoral na€ıve T cells increases significantly with tumor progression. Tumor cell suspensions were stained
with CD4-, CD44-, CCR7- and CD62L-specific mAbs and analyzed by flow cytometry. Proportions of CD41CD44loCD62L1 cells were analyzed
with respect to tumor weight at the time of sample preparation (a). Frequency of na€ıve CD41 TILs in small versus large tumor (b). In (c),
Foxp31 cells were excluded from the analysis to more accurately demonstrate the relationship between na€ıve CD41 cells and tumor weight.
The relationship between CD41Foxp31 cells and tumor weight (d). The relationship between activated effector CD41Foxp32 TILs and tumor
weight (e).
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Proportions of na€ıve CD41 T cells increase with tumor
progression but fail to become activated
When we examined TIL composition in small versus large
tumors, the results were striking, revealing that the proportion
of CD41CD44loCD62LhiCCR71 T cells increases signiﬁcantly
as tumors progress (Fig. 6a). This was owing to an increase in
the proportion of CD41Foxp32 CD44loCD62LhiCCR71 T cells
(Figs. 6b and 6c) and not owing to an increase in
CD41Foxp31 T cells which are likely to prevent their intratu-
moral activation (Fig. 6d). Furthermore, the proportion of
CD41Foxp32 TILs with an activated effector phenotype
decreased with tumor progression (Fig. 6e). These data indi-
cate that na€ıve conventional CD41 T cells accumulate with
tumor progression, eventually outnumbering both effector/
memory T cells and Tregs in larger tumors.
To determine whether the intratumoral na€ıve T cells
become activated within the tumor, we performed TCR clo-
notyping where we compared the repertoires of na€ıve
(CD44loCD62Lhi) and activated T cells (CD44hiCD62Llo)
within the intratumoral and draining lymph node
CD41Foxp32 T-cell populations.6,22 We found that although
there was a pronounced narrowing of the TCR repertoire
and expansion of certain clonotypes within the intratumoral
activated T-cell population, a similar pattern was not
observed among the CD44loCD62Lhi population (Supporting
Information Fig. 4). These data support the premise that
tumor-speciﬁc T cells are activated in the draining lymph
node before migrating to the tumor, where they expand in
an antigen-driven fashion and exert their antitumor effects.
Discussion
Through a detailed examination of tumor-inﬁltrating T cells,
our study has revealed that na€ıve T cells can accumulate
within tumors. The key questions that arise from this ﬁnding
relate to the route through which T cells may access a tumor
mass and the implications of this event for tumor progres-
sion. It has been reported previously that a measureable
number of na€ıve T cells can enter nonlymphoid organs under
normal homeostatic conditions (reviewed in Refs. 11,23,24).
In these previous studies, where na€ıve T cells have been
recovered from nonlymphoid organs, the numbers were
reportedly low constituting but a very small proportion of T
cells migrating through the tissues.11 We surmized that
mechanisms allowing the inﬂux of na€ıve T cells into tumors
must therefore be distinct from those deﬁning the normal
migratory pathway of na€ıve T cells as proportions of na€ıve T
cells, at least within MCA-induced ﬁbrosarcomas are very
high and signiﬁcantly, increase during tumor progression.
This observation points to alterations in the tumor architec-
ture that allow inﬂux of na€ıve T cells. Our investigations pro-
duced clear evidence for blood vessel leakage within the
ﬁbrosarcomas, indicating that this was at least one point
through which na€ıve T cells could enter the tumor mass. We
also examined whether T-cell ingress might occur via lym-
phatics. Injection of dextran–FITC at the base of the tumor-
bearing leg resulted in ingress of dye into the tumor, suggest-
ing that lymph can indeed access the tumor. Moreover, both
CCR72/2 and CCR71/1 T cells injected into the skin adja-
cent to primary ﬁbrosarcomas could be recovered from the
tumor tissue within 18 hr. Although the mechanism by
which this occurs remains unclear, the implication is that
na€ıve T cells, reported to be present in the skin, can enter
tumors via lymphatics. These may be co-opted skin lym-
phatics that enter the tumor or newly formed lymphatics
induced by the tumor. As a result of the perturbed environ-
ment created by the tumor, the nature of these lymphatic
vessels may allow entry of T cells via CCR7-independent
mechanisms.
Collectively, the data described above point to two routes
whereby na€ıve T cells might access the tumor parenchyma in
an antigen nonspeciﬁc manner. The fate of these na€ıve T
cells is, however, unclear. Other studies using largely trans-
genic T cells indicate that T-cell priming can occur within a
tumor mass. Through transfecting tumor cells with LIGHT, a
cytokine capable of driving development of HEV in tumors,
it has been shown that na€ıve transgenic T cells entering via
these HEV can become primed within the tumor and con-
tribute signiﬁcantly to limiting tumor progression.25 Simi-
larly, delivery of lymphotoxin-a fused to tumor-speciﬁc
antibodies induces HEV development in B16 melanoma,
resulting in inﬁltration and priming of effective antitumor T
cells.26 In another study, adoptively transferred na€ıve trans-
genic T cells were shown to inﬁltrate tumors where they
became activated and proliferated in response to antigens
presented by cells within the tumor parenchyma.27 These
reports are interesting as they demonstrate the potential for
T-cell priming in tumors and the capacity for this event to
contribute to control of tumor growth. Our data, however,
argue that in the case where physiological precursor frequen-
cies of T cells capable of recognizing tumor antigens are
present within the na€ıve T-cell pool, and when antigen-
driven signals are not required for guiding entry of the cells
into tumors, these na€ıve T cells probably make little, if any
contribution to the antitumor immune response.
Although the T cells that enter via the routes, described
above, may play little role in shaping the progression of the
tumor, our study has uncovered a hitherto unreported event
namely the capacity of tumor-associated lymphatics to deliver
lymph to the tumor. Normally such vessels drain interstitial
ﬂuids as well as antigens and various other soluble factors for
ﬁltration to downstream lymph nodes, in response to the
raised interstitial pressure within the tumor body.28 It is possi-
ble that delivery of lymph represents an important step in pro-
moting the acquisition of lymphoid-like features in tumors. It
is known that activated cells and not na€ıve T cells home to
sites of inﬂammation, whereas effector cells tend to be
excluded from lymphoid organs29 and thus acquisition of
lymphoid-like features by tumors is very likely to shape the
nature of the immune inﬁltrate present within the tumor
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microenvironment. Our understanding of how such events
contribute to induction of tolerance versus immunity remains,
however, extremely poor. Shields et al.20 recently reported that
overexpression of CCL21 in tumors can promote the develop-
ment of lymphoid structures, inducing local immunological
tolerance through facilitating migration and retention of Tregs.
On the other hand, in a study of more than 300 breast
tumors, it was reported that HEV, specialized blood vessels
normally found only in secondary lymphoid organs, could be
identiﬁed in tumors. In this case, the presence of CCL21 was
associated with HEV and inﬁltration of large numbers of effec-
tor T cells, the presence of which was indicative of a good
prognosis.30 The impact of CCL21 expression may not be the
same in all tumors. Although Shields et al.20 reported Treg
accumulation in rapidly progressing orthotopic tumors
expressing CCL21, we observed an accumulation of na€ıve T
cells in carcinogen-induced tumors that develop in vivo over a
period of months. Our experiments indicate no role, however,
for CCL21 in guiding entry of T cells into tumors at least not
via the lymphatics. What role might CCL21 therefore play?
Previous experiments tracking the migration and accumulation
of rat lymphocytes have revealed that although na€ıve T cell
numbers increase in lymph nodes over time, their numbers in
nonlymphoid organs remain constant or decrease over time
(reviewed in Ref. 23). Perhaps CCL21 in the tumor serves to
position and/or retain na€ıve T cells within the tumor mass,
thereby facilitating their accumulation and allowing them to
become more abundant as tumors progress. Further experi-
ments are required to test this hypothesis.
It is noteworthy that experiments carried out previously
have demonstrated that afferent lymph is required to main-
tain HEV in lymph nodes.18,31,32 In these experiments, shut-
down of afferent lymphatics was shown to signiﬁcantly
reduce HEV in lymph nodes with concomitant reduction in
the degree of lymphocytic inﬁltrate. Although no HEV could
be detected in the MCA-induced tumors described here, it
has been previously shown by our group that HEV can
develop in these tumors when Tregs are depleted.14 It is thus
possible that delivery of lymph, which may provide a source
of key factors such as chemokines and cytokines, is essential
for this process.32,33 It is also tempting to speculate that the
development of afferent-like lymphatics may be an essential
prerequisite to HEV development in tumors, thereby forming
an important part of facilitating an effective antitumor
immune response.
Outgrowth of tumors may, at least in part, be owing to a
failure of the immune response (reviewed in Ref. 2). This
failure has been attributed, among other things, to loss of
immunogenicity, anergy, suppression by Tregs and myeloid-
derived suppressor cells. It is becoming increasingly clear that
the tumor microenvironment, speciﬁcally blood vessels and
lymphatics feeding the tumor, dictate the immunological
composition of tumor-inﬁltrating leukocytes. In case of some
tumors, this may be through the development of a lymphoid-
like stroma that promotes accumulation of Tregs. However,
in the case of the tumors described here, where CCL21 is
expressed on lymphatic endothelial cells and lymph is deliv-
ered to the tumors, the result is the accumulation of antigen
nonspeciﬁc na€ıve T cells and a complete failure to drive an
antitumor immune response. It is possible that these na€ıve T
cells impinge on the antitumor immune response by compet-
ing with effector T cells for important nutrients and resour-
ces. Understanding the signals that dictate the nature of the
tumor microenvironment should enable manipulation of the
composition of the tumor-inﬁltrating T-cell pool to tip the
balance away from tolerance or nonresponsiveness and
toward the development and maintenance of a productive
response capable of sustained elimination of the tumor cells.
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